Technical Analysis for LQDA - Liquidia Technologies, Inc.

Grade Last Price % Change Price Change
C 10.63 -0.93% -0.10
LQDA closed down 0.93 percent on Tuesday, November 12, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Nov 13
*** please verify all earnings dates ***
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
Bearish Engulfing Bearish -0.93%
Fell Below 20 DMA Bearish -0.93%
Bollinger Band Squeeze Range Contraction -0.93%
Crossed Above 20 DMA Bullish -3.63%
Bollinger Band Squeeze Range Contraction -3.63%
Up 3 Days in a Row Strength -3.63%
Bollinger Band Squeeze Range Contraction -1.85%
Lower Bollinger Band Walk Weakness -1.85%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 4 hours ago
10 DMA Resistance about 6 hours ago
Down 2 % about 6 hours ago
60 Minute Opening Range Breakdown about 6 hours ago
Down 1% about 7 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Liquidia Technologies, Inc. Description

Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Pain Medication Hypertension Opioids Clinical Trial Uniform Pulmonary Arterial Hypertension Bupivacaine Inhaler Treprostinil

Is LQDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.99
52 Week Low 6.0993
Average Volume 910,622
200-Day Moving Average 12.42
50-Day Moving Average 10.46
20-Day Moving Average 10.97
10-Day Moving Average 10.76
Average True Range 0.40
RSI (14) 46.24
ADX 25.05
+DI 23.18
-DI 18.76
Chandelier Exit (Long, 3 ATRs) 10.63
Chandelier Exit (Short, 3 ATRs) 11.38
Upper Bollinger Bands 11.54
Lower Bollinger Band 10.39
Percent B (%b) 0.21
BandWidth 10.55
MACD Line 0.00
MACD Signal Line 0.06
MACD Histogram -0.056
Fundamentals Value
Market Cap 805.88 Million
Num Shares 75.8 Million
EPS -0.88
Price-to-Earnings (P/E) Ratio -12.08
Price-to-Sales 61.30
Price-to-Book 23.37
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.09
Resistance 3 (R3) 11.10 10.96 11.01
Resistance 2 (R2) 10.96 10.84 10.95 10.99
Resistance 1 (R1) 10.79 10.77 10.72 10.78 10.96
Pivot Point 10.65 10.65 10.62 10.65 10.65
Support 1 (S1) 10.49 10.54 10.42 10.48 10.30
Support 2 (S2) 10.35 10.46 10.34 10.27
Support 3 (S3) 10.18 10.35 10.25
Support 4 (S4) 10.17